Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab and CIK Cells in Metastatic Clear Cell Renal Cell Carcinoma
NCT03987698Phase 2Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jun 2019
- Primary completion
- Jun 2022
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of unmodified CIK in clear cell renal cell carcinoma (ccRCC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Status: unknown.
02
Drugs
unmodified CIK
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT03987698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03987698.